AI Article Synopsis

  • Common Variable Immunodeficiency Disorders (CVID) are characterized by recurrent infections and a range of non-infectious complications, with this study focusing on the differences in these complications in patients with and without interstitial lung disease (ILD).
  • In a study of 129 patients, it was found that 62% had chronic lung issues, with bronchiectasis being particularly common, leading to worse lung function among those with CVID-ILD compared to those without.
  • The research underscores the importance of a multidisciplinary approach to managing CVID, given the high prevalence of lung complications and the need for targeted treatments, such as immunosuppressive therapies, especially in those with ILD.

Article Abstract

Background: Common Variable Immunodeficiency Disorders (CVID) encompass a spectrum of immunodeficiency characterised by recurrent infections and diverse non-infectious complications (NICs). This study aimed to describe the clinical features and variation in NICs in CVID with and without interstitial lung disease (ILD) from a large UK national registry population.

Methods: Retrospective, cross-sectional data from a UK multicentre database (previously known as UKPIN), categorising patients into those with CVID-ILD and those with NICs related to CVID but without pulmonary involvement (CVID-EP; EP= extra-pulmonary involvement only).

Results: 129 patients were included. Chronic lung diseases, especially CVID-ILD, are prominent complications in complex CVID, occurring in 62% of the cohort. Bronchiectasis was common (64% of the cohort) and associated with greater pulmonary function impairment in patients with CVID-ILD compared to those without bronchiectasis. Lymphadenopathy and the absence of gastrointestinal diseases were significant predictors of ILD in complex CVID. Although the presence of liver disease did not differ significantly between the groups, nearly half of the CVID-ILD patients were found to have liver disease. Patients with CVID-ILD were more likely to receive immunosuppressive treatments such as rituximab and mycophenolate mofetil than the CVID-EP group, indicating greater need for treatment and risk of complications.

Conclusion: This study highlights the significant burden of CVID-ILD within the CVID population with NICs only. The lungs emerged as the most frequently affected organ, with ILD and bronchiectasis both highly prevalent. These findings emphasise the necessity of a comprehensive and multidisciplinary approach in managing CVID patients, considering their susceptibility to various comorbidities and complications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420000PMC
http://dx.doi.org/10.3389/fimmu.2024.1451813DOI Listing

Publication Analysis

Top Keywords

patients cvid-ild
12
non-infectious complications
8
common variable
8
variable immunodeficiency
8
immunodeficiency disorders
8
nics cvid
8
complex cvid
8
liver disease
8
cvid
7
patients
6

Similar Publications

Article Synopsis
  • Common Variable Immunodeficiency Disorders (CVID) are characterized by recurrent infections and a range of non-infectious complications, with this study focusing on the differences in these complications in patients with and without interstitial lung disease (ILD).
  • In a study of 129 patients, it was found that 62% had chronic lung issues, with bronchiectasis being particularly common, leading to worse lung function among those with CVID-ILD compared to those without.
  • The research underscores the importance of a multidisciplinary approach to managing CVID, given the high prevalence of lung complications and the need for targeted treatments, such as immunosuppressive therapies, especially in those with ILD.
View Article and Find Full Text PDF

Introduction: Common variable immunodeficiency related interstitial lung disease (CVID-ILD, also referred to as GLILD) is generally considered a manifestation of systemic immune dysregulation occurring in up to 20% of people with CVID. There is a lack of evidence-based guidelines for the diagnosis and management of CVID-ILD.

Aim: To systematically review use of diagnostic tests for assessing patients with CVID for possible ILD, and to evaluate their utility and risks.

View Article and Find Full Text PDF

Granulomatous and Lymphocytic Interstitial Lung Diseases (GLILD) is a severe non-infectious complication of Common Variable Immunodeficiency (CVID), often associated with extrapulmonary involvement. Due to a poorly understood pathogenesis, GLILD diagnosis and management criteria still lack consensus. Accordingly, it is a relevant cause of long-term loss of respiratory function and is closely associated with a markedly reduced survival.

View Article and Find Full Text PDF

B Cell Dysregulation in Common Variable Immunodeficiency Interstitial Lung Disease.

Front Immunol

June 2021

Pulmonary Center, Section of Pulmonary, Allergy, Sleep & Critical Care Medicine, Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, United States.

Common variable immunodeficiency (CVID) is the most frequently diagnosed primary antibody deficiency. About half of CVID patients develop chronic non-infectious complications thought to be due to intrinsic immune dysregulation, including autoimmunity, gastrointestinal disease, and interstitial lung disease (ILD). Multiple studies have found ILD to be a significant cause of morbidity and mortality in CVID.

View Article and Find Full Text PDF

Bronchoalveolar Lavage Fluid Reflects a T1-CD21 B-Cell Interaction in CVID-Related Interstitial Lung Disease.

Front Immunol

June 2021

Divison of Immunodeficiency, Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Background: About 20% of patients with common variable immunodeficiency (CVID) suffer from interstitial lung disease (ILD) as part of a systemic immune dysregulation. Current understanding suggests a role of B cells in the pathogenesis based on histology and increased levels of BAFF and IgM associated with active disease corroborated by several reports which demonstrate the successful use of rituximab in CVID-ILD. It is debated whether histological confirmation by biopsy or even video-assisted thoracoscopy is required and currently not investigated whether less invasive methods like a bronchoalveolar lavage (BAL) might provide an informative diagnostic tool.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!